Results 101 to 110 of about 35,440 (172)

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, Volume 138, Issue 2, Page 219-228, August 2026.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Translating Asian‐Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021–2025

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT An increasing number of novel molecular entities and biosimilars reach the European Medicines Agency (EMA) supported by pivotal evidence derived predominantly from Asian patient populations. This creates regulatory challenges that the existing ICH E5 framework was not originally designed to address.
Prerona Boruah, Alex Zwiers
wiley   +1 more source

<i>PARP9</i> Modulates Sunitinib Resistance in Clear Cell Renal Cell Carcinoma via <i>STAT1</i>/<i>IRF1</i> Signaling Pathway. [PDF]

Oncol Res
Luo L, Guan F, Wang Z, Li B, Ding X, Song L, Sun L.   +6 more
europepmc   +1 more source

Early-Onset Posterior Reversible Encephalopathy Syndrome at Reduced-Dose Sunitinib in Metastatic Papillary Renal Cell Carcinoma: A Case Report. [PDF]

Case Rep Med
Aslan F, Erkılıç B, Günaydın E, Gençler OS, Taban H.   +4 more
europepmc   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

A comprehensive analysis of the adverse drug events of metastatic and unresectable gastrointestinal stromal tumor treatment options: avapritinib, imatinib, regorafenib, ripretinib, and sunitinib safety insights and implications. [PDF]

Future Sci OA
Thompson CM, Andrews MB, Adler DG.
europepmc   +1 more source

Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters. [PDF]

J Clin Invest
Haddad G, Guo J, Xi Y, Albayrak E, Huseni M, Hamidi H, Banchereau R, Kadel E, Dubey S, Carter C, Kapur P, Brugarolas J, Pedrosa I.   +12 more
europepmc   +1 more source

Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib. [PDF]

Cancer Chemother Pharmacol
Sałek-Zań A, Mirosława P, Agnieszka S, Justyna J, Agnieszka P, Aleksandra GW, Maciej S, Tomasz B.   +7 more
europepmc   +1 more source

Dual-target neoadjuvant therapy with denosumab and sunitinib for giant cell tumor of bone: a sarcoma center experience. [PDF]

J Bone Oncol
Mahdal M, Apostolopoulos V, Múdrý P, Neradil J, Kubíček M, Zoufalý D, Adámková D, Tomáš T.   +7 more
europepmc   +1 more source